Search Orphan Drug Designations and Approvals
-
| Generic Name: | antibody-drug conjugate (ADC) consisting of a fully human, Fc-silenced IgG1 anti-claudin 18.2 monoclonal antibody, a cleavable linker, and exatecan, a topoisomerase I inhibitor |
|---|---|
| Date Designated: | 02/24/2025 |
| Orphan Designation: | treatment of pancreatic cancer |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Takeda Development Center Americas, Inc. 500 Kendall Street Cambridge, Massachusetts 02142 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







